DoSES

DoSES

Contact

 If you are interested in participating in the study or want to learn more, please get in touch. Contact us
This study is now recruiting. Learn more about enrolling here.

Description

This research is studying a vaccine against Mpox (formerly known as monkeypox) that is FDA approved for adults but not yet approved for children. The goal of the study is to determine if the vaccine protects children just as well as it protects adults. The study is also looking at the safety of the vaccine. This study is open to healthy adolescents, ages 12-17. In addition, adolescents with certain immunodeficiency diseases or other conditions, that are well controlled, are eligible to participate.

Eligibility and criteria
IRB Number:
23-020826
Eligible age range:
12 years - 17 years
Clinical trial phase:
Phase II
Official title:
A Phase 2 Randomized, Open-Label, Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox

What to expect

Your participation would consist of your child completing the following:

  • Attend 9 study visits over a 13-month period. 8 study visits will be held in person at the CHOP Main Campus, and 1 study visit will be done over the phone.
  • Receive 2 doses of the Jynneos Mpox vaccine, 29 days apart
  • Have blood drawn at 5 of the 9 study visits
Participation is voluntary. There would be no cost to you, and you would be compensated for your time and effort.

Related specialties
Smiling CHOP patient holding shopping bag

We need families like you

Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.